Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Stroke ; 43(3): 802-7, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22207506

ABSTRACT

BACKGROUND AND PURPOSE: Although secondary medical prevention strategies in patients with stroke are well established, only sparse data exist regarding their effectiveness in routine care. We examined the effectiveness in a nationwide, population-based follow-up study. METHODS: Using data from the Danish National Indicator Project (DNIP), 28,612 patients hospitalized for ischemic stroke in 2003 to 2006 were identified. Information on drug use and outcomes was by individual-level record linkage with national medical databases. Hazard ratios were computed for death, myocardial infarction, and recurrent stroke according to drug use after hospital discharge. RESULTS: Treatment with antiplatelets, oral anticoagulants, antihypertensives, or statins was associated with a lower risk of the combined end point of death, myocardial infarction, or recurrent stroke during a mean follow-up period of 2.7 years (adjusted hazard ratios [HRs] from 0.44 [95% CI, 0.39-0.49] to 0.94 [95% CI, 0.89-0.99]). All drug classes were associated with lower risk of death (adjusted HRs from 0.36 [95% CI, 0.32-0.41] to 0.85 [95% CI, 0.80-0.90]), with oral anticoagulant treatment in patients with atrial fibrillation being particularly effective in elderly women (>80 years; adjusted HR, 0.35; 95% CI, 0.28-0.45). Oral anticoagulant treatment was associated with a lower risk of recurrent stroke (adjusted HR, 0.58; 95% CI, 0.47-0.73), and statins were associated with a lower risk of myocardial infarction (adjusted HR, 0.84; 95% CI, 0.73-0.97) and recurrent stroke (adjusted HR, 0.86; 95% CI, 0.79-0.92). CONCLUSIONS: Secondary medical prophylaxis after ischemic stroke was associated with improved outcome in routine settings. Although these findings are of an observational nature, they tend to support the results from previous randomized trials.


Subject(s)
Brain Ischemia/prevention & control , Brain Ischemia/therapy , Stroke/prevention & control , Stroke/therapy , Aged , Anticoagulants/therapeutic use , Antihypertensive Agents/therapeutic use , Brain Ischemia/mortality , Cerebral Hemorrhage/mortality , Cerebral Hemorrhage/therapy , Data Interpretation, Statistical , Denmark/epidemiology , Female , Follow-Up Studies , Guidelines as Topic , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/prevention & control , Patient Discharge , Platelet Aggregation Inhibitors/therapeutic use , Propensity Score , Proportional Hazards Models , Randomized Controlled Trials as Topic , Risk Factors , Secondary Prevention , Stroke/mortality , Treatment Outcome
2.
Cerebrovasc Dis ; 30(6): 556-66, 2010.
Article in English | MEDLINE | ID: mdl-20948199

ABSTRACT

BACKGROUND: The extent and implications of age- and sex-related differences in prophylaxis following ischemic stroke are unknown. We examined differences in the use of medical prophylaxis across age and sex groups in stroke patients after hospital discharge in Denmark and estimated the possible impact on age- and sex-related differences in mortality. METHODS: A nationwide population-based follow-up study was conducted involving 28,634 patients hospitalized for ischemic stroke in 2003-2006 who survived 30 days after discharge. The proportion of patients who filled prescriptions for cardiovascular drugs within 0-6 and 12-18 months after discharge was determined. Mortality rates were compared across age and sex groups with and without controlling for use of medical prophylaxis. RESULTS: Increasing age was associated with lower prophylaxis. Adjusted odds ratios for the use of a combination of a platelet inhibitor, an antihypertensive and a statin were 0.45 [95% confidence interval (CI): 0.38-0.54] and 0.52 (95% CI: 0.43-0.62) for men and women >80 years, respectively, compared with men ≤65 years. No systematic sex-related differences were identified. Continued drug use ranged from 66.1 to 91.9% for different drugs 12-18 months after discharge, with the lowest rate of continued use found among patients >80 years. Controlling for use of medical prophylaxis was associated with lower mortality rate ratios for elderly compared with younger patients. CONCLUSIONS: Continuous efforts are warranted to ensure implementation of evidence-based secondary prophylaxis among elderly patients with ischemic stroke.


Subject(s)
Brain Ischemia/drug therapy , Brain Ischemia/mortality , Cardiovascular Agents/therapeutic use , Hospitalization/statistics & numerical data , Patient Discharge/statistics & numerical data , Secondary Prevention/statistics & numerical data , Stroke/drug therapy , Stroke/mortality , Age Factors , Aged , Aged, 80 and over , Denmark , Drug Prescriptions/statistics & numerical data , Evidence-Based Medicine , Female , Follow-Up Studies , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Practice Guidelines as Topic , Proportional Hazards Models , Prospective Studies , Registries , Risk Assessment , Risk Factors , Sex Factors , Time Factors , Treatment Outcome
3.
Int J Qual Health Care ; 16 Suppl 1: i45-50, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15059986

ABSTRACT

OBJECTIVE: In most countries there is no mandatory national system to track the quality of care delivered to the citizens. This paper describes an example of a national indicator project that aims at documenting and improving the quality of care nationwide. ANALYSIS: The Danish National Indicator Project was established in 2000 as a nationwide multidisciplinary quality improvement project. From 2000 to 2002, disease-specific clinical indicators and standards were developed for six diseases (stroke, hip fracture, schizophrenia, acute gastrointestinal surgery, heart failure, and lung cancer). Indicators and standards have been implemented in all clinical units and departments in Denmark treating patients with the six diseases, and participation is mandatory. All clinical units and departments receive their results every month. National and regional audit processes are organized to explain the results and to prepare implementation of improvements. All results are published in order to inform the public, and to give patients and relatives the opportunity to make informed choices. CONCLUSION: The surveillance of health care quality is greatly aided by the use of relevant quantitative indicators. This paper describes how it is possible to organize nationwide monitoring using clinical indicators.


Subject(s)
Delivery of Health Care , Total Quality Management , Delivery of Health Care/organization & administration , Delivery of Health Care/standards , Denmark
SELECTION OF CITATIONS
SEARCH DETAIL
...